Targeting the Notch1-Jagged1/NF-κB(p65) Pathway: Can Bruceine D Inhibit CAF-Mediated Triple-Negative Breast Cancer Metastasis?

1. Concept

Triple-negative breast cancer (TNBC) is an aggressive subtype with a poor prognosis, characterized by the lack of effective therapeutic targets and a high propensity for distant metastasis. The tumor microenvironment (TME) plays a pivotal role in driving TNBC progression, with cancer-associated fibroblasts (CAFs) as the most abundant stromal cell population. Activated CAFs secrete pro-inflammatory factors, growth factors, and matrix-remodeling enzymes, forming a pro-metastatic niche. Tumor necrosis factor-alpha (TNF-α) acts as a core mediator in the "tumor-CAF-inflammation" malignant network, amplifying crosstalk between CAFs and tumor cells. Bruceine D, a natural active compound extracted from the traditional Chinese herb Brucea javanica, has emerged as a potential anti-metastatic agent. Its mechanism of action centers on targeting the Notch1-Jagged1/NF-κB(p65) signaling pathway—a key hub regulating CAF-tumor cell interactions. The NF-κB p65 (Ser536) phosphorylation antibody, a high-specificity research tool, enables precise assessment of pathway activation, supporting the elucidation of Bruceine D’s therapeutic potential.

2. Research Frontiers

2.1 The "Tumor-CAF-Inflammation" Network Driving TNBC Metastasis

The TME’s "tumor-CAF-inflammation" axis is a critical driver of TNBC metastasis:

• CAFs, the most abundant stromal cells in the TME, secrete factors such as IL-6, CXCL12, TGF-β, and MMPs, creating a pro-invasive and pro-inflammatory microenvironment.
• TNF-α, excessively present in the TME, stimulates both tumor cells and CAFs, initiating and amplifying malignant crosstalk between them.
• This interconnected network enhances tumor cell migration, invasion, and distant metastasis, making key signaling hubs within the axis prime therapeutic targets.

2.2 Bruceine D Inhibits CAF-Mediated Pro-Metastatic Effects Under TNF-α Stimulation

In vitro experiments simulating the TNF-α-enriched TME (co-culturing CAFs with TNBC cells like MDA-MB-231) revealed:

• TNF-α stimulation significantly enhances the migratory and invasive abilities of TNBC cells in co-culture.
• Bruceine D treatment dose-dependently suppresses this CAF-mediated pro-metastatic effect.
• Mechanistically, Bruceine D reduces the secretion of pro-metastatic factors (TNF-α, IL-6, CXCL12, TGF-β1, MMP-9) in the co-culture supernatant, inhibiting CAF activation and their secretory phenotype at the source.

2.3 The Notch1-Jagged1/NF-κB(p65) Pathway as the Core Target of Bruceine D

The Notch1-Jagged1 and NF-κB(p65) pathways synergize to drive TNBC metastasis, with Bruceine D disrupting this crosstalk:

• In the TNF-α-stimulated co-culture system, Notch1-Jagged1 signaling and NF-κB(p65) are synergistically activated, forming a positive feedback loop that sustains pro-inflammatory and pro-metastatic gene expression.
• Western blot analysis confirms Bruceine D reduces levels of the Notch1 intracellular domain (NICD), Jagged1, and phosphorylated (activated) NF-κB p65 in both CAFs and tumor cells.
• This dual inhibition blocks the mutual activation of the two pathways, breaking the malignant cycle of CAF-tumor cell crosstalk.

2.4 The Key Role of the NF-κB p65 (Ser536) Phosphorylation Antibody in Mechanistic Studies

The NF-κB p65 (Ser536) phosphorylation antibody is indispensable for validating pathway inhibition:

• Precise activation assessment: Used in Western blot and immunohistochemistry (IHC) to quantify reduced p-p65 (Ser536) levels after Bruceine D treatment, directly confirming NF-κB pathway inhibition.
• Revealing pathway crosstalk: By correlating p-p65 (Ser536) expression with Notch1/Jagged1 levels, the antibody helps elucidate molecular links between the two pathways.
• Functional phenotype correlation: Links p-p65 (Ser536) inhibition to reduced pro-inflammatory factor secretion and diminished cell invasiveness, constructing a complete "target inhibition → functional output" evidence chain.

2.5 In Vivo Efficacy of Bruceine D in Inhibiting TNBC Growth and Metastasis

TNBC xenograft mouse models validate Bruceine D’s preclinical potential:

• Bruceine D significantly inhibits primary tumor growth and reduces lung/liver metastatic lesions.
• Tumor tissue analysis shows: reduced α-SMA-positive activated CAFs (IHC/immunofluorescence), diminished abnormal collagen deposition (Masson/Sirius Red staining), and downregulated Notch1, Jagged1, and p-p65 protein expression (Western blot).
• These findings confirm Bruceine D disrupts the pro-metastatic TME by targeting CAF activation and the Notch1-Jagged1/NF-κB(p65) axis in vivo.

3. Research Significance

This study holds profound scientific and translational significance for TNBC treatment:

• Scientific value: It is the first to link Bruceine D to the Notch1-Jagged1/NF-κB(p65) pathway, uncovering a novel mechanism by which natural compounds target the "tumor-CAF-inflammation" network. It also validates the NF-κB p65 (Ser536) antibody as a critical tool for pathway analysis.
• Translational value: Bruceine D emerges as a promising anti-metastatic agent for TNBC, a disease with limited therapeutic options. The research provides a theoretical basis for developing Bruceine D into a clinical drug, while the identified pathway offers potential biomarkers for patient stratification.

4. Related Mechanisms, Research Methods, and Product Applications

4.1 Core Mechanism of Bruceine D’s Anti-Metastatic Effect

Bruceine D inhibits TNBC metastasis through a multi-step pathway:

1. TNF-α stimulates CAFs and tumor cells, activating the Notch1-Jagged1/NF-κB(p65) positive feedback loop.
2. Activated pathways promote CAF activation and secretion of pro-metastatic factors (IL-6, TGF-β1, MMP9) and ECM remodeling.
3. Bruceine D blocks Notch1-Jagged1 signaling and NF-κB(p65) phosphorylation (Ser536), inhibiting CAF activation and pro-metastatic factor secretion.
4. Reduced pro-metastatic signals and ECM remodeling suppress tumor cell migration, invasion, and distant metastasis.

4.2 Key Research Methods

The study integrates in vitro and in vivo approaches, with the NF-κB p65 (Ser536) antibody as a core tool:

• In vitro co-culture assays: Evaluating CAF-tumor cell crosstalk under TNF-α stimulation and Bruceine D’s effects on cell migration/invasion.
• Western blot/IHC/immunofluorescence: Using the NF-κB p65 (Ser536) antibody to detect pathway activation; assessing CAF activation (α-SMA) and ECM remodeling (collagen staining).
• In vivo xenograft models: Testing Bruceine D’s efficacy in inhibiting tumor growth and metastasis; validating pathway inhibition in tumor tissues.
• Factor secretion analysis: Quantifying pro-metastatic factor levels in supernatants via ELISA.

4.3 Product Applications: ANT BIO PTE. LTD.’s NF-κB p65 (Ser536) Recombinant Rabbit Monoclonal Antibody

ANT BIO PTE. LTD.’s STARTER brand offers the “Phospho-NF-κB p65 (Ser536) Recombinant Rabbit mAb (Catalog No.: S0B1035)”—a high-performance tool for detecting NF-κB pathway activation.

Core Product Advantages

• High phosphorylation site specificity: Specifically recognizes NF-κB p65 phosphorylated at Ser536, a key activation marker for canonical NF-κB signaling, closely linked to p65 nuclear translocation and transcriptional activity.
• Multi-platform validation: Validated for Western blot (WB), immunofluorescence (IF), flow cytometry, and IHC, ensuring versatility across research methods.
• Stability and batch consistency: Strict quality control ensures minimal batch-to-batch variation, supporting reliable and reproducible results.

Key Application Scenarios

• Inflammatory signaling research: Detecting p65 Ser536 phosphorylation after inflammatory stimuli (TNF-α, IL-1β, LPS) to assess NF-κB pathway activation.
• Immune cell function studies: Analyzing NF-κB activation in immune cells (T cells, macrophages) and its role in cytokine secretion and proliferation.
• Tumor research: Investigating constitutive or inducible NF-κB activation in tumors (TNBC, lymphoma, colorectal cancer) and its role in proliferation, apoptosis, and therapy resistance.
• Drug mechanism validation: Assessing the efficacy of pathway-targeted drugs (e.g., Bruceine D) in inhibiting NF-κB activation.

ANT BIO PTE. LTD. provides comprehensive technical support, including phosphorylation dynamics data, nuclear localization assessment protocols, and expert consultation for experimental design.

5. Brand Mission

ANT BIO PTE. LTD. is dedicated to empowering the global life science community with high-quality, innovative research tools and solutions. As a leader in life science reagents, we offer a comprehensive portfolio under three sub-brands: Absin (focused on general reagents and kits), Starter (specialized in antibodies), and UA (dedicated to recombinant proteins).

Our commitment to excellence is underpinned by advanced development platforms—including recombinant rabbit/mouse monoclonal antibody platforms, rapid monoclonal antibody development, recombinant protein expression systems (E. coli, CHO, HEK293, Insect Cells), One-Step ELISA Platforms, and PTM Pan-Modification Antibody Platforms—alongside rigorous quality control systems. We hold international certifications such as EU 98/79/EC, ISO9001, and ISO13485, ensuring our products meet the highest global standards.

Our mission is to accelerate scientific discovery, facilitate translational research, and contribute to the development of novel therapies for human health. By partnering with researchers in academia and biopharmaceutical companies worldwide, we strive to be a trusted collaborator in advancing life science research and addressing unmet medical needs.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.